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Abstract
Background: Overweight and obesity, due to a Westernized diet and lack of exercise, are serious global problems that negatively
affect not only personal health, but national economies as well. To solve these problems, preventative-based approaches should
be taken rather than medical treatments after the occurrence of disease. The improvement of individual life habits, through
continuous care, is thus a paramount, long-term treatment goal. This study describes the effects of ubiquitous health care (uHealth
care) or SmartCare services in the treatment of weight loss and obesity.
Objective: The aim of this study is to evaluate the effect of SmartCare services on weight loss compared to the effects of existing
outpatient treatments in obese patients with metabolic syndrome.
Methods: Metabolic syndrome patients who met the inclusion/exclusion criteria were enrolled in the study and randomized
into an intervention or control group. The intervention group was provided with remote monitoring and health care services in
addition to the existing treatment. The control group was provided with only the existing treatment. Pedometers were given to
all of the patients. Additionally, mobile phones and body composition monitors were provided to the intervention group while
body weight scales were provided to the control group. The patients visited the hospitals at 12 and 24 weeks following the baseline
examination to receive efficacy and safety evaluations.
Results: Mean weight reduction from baseline to week 24 was measured as a primary efficacy evaluation parameter and was
found to be 2.21 kg (SD 3.60) and 0.77 kg (SD 2.77) in the intervention and control group, respectively. The intervention group
had a larger decrement compared to the control group (P<.001). Among the secondary efficacy evaluation parameters, body mass
index (BMI) (P<.001), body fat rate (P=.001), decrement of waist measurement (P<.001), and diet habit (P=.012) improvement
ratings from baseline to week 24 were found to be superior in the intervention group compared with the control group. The
proportion of patients whose body weight decreased by ≥10%, lipid profiles, blood pressure, prevalence of metabolic syndrome,
change in the number of metabolic syndrome elements, smoking rate, drinking rate, and physical activity were not statistically
significant between the groups.
Conclusions: The efficacy of SmartCare services was confirmed as the intervention group that received both SmartCare services
and the existing treatment had superior results compared with the control group that only received the existing treatment.
Importantly, no specific problems with respect to safety concerns were observed. SmartCare service is thus an effective way to
control the weight of obese patients with metabolic syndrome.
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Introduction
Obesity increases the prevalence of diabetes mellitus type 2,
metabolic syndrome, cardiovascular diseases, and the mortality
rate [1]. Metabolic syndrome is a condition in which various
cardiovascular and metabolic risk factors are simultaneously
present because of insulin resistance, obesity, and other factors,
causing cardiovascular diseases, the main causes of death [2,3].
The specific cause of metabolic syndrome is unknown, but it
is important to control body weight because obesity and insulin
resistance are suspected to be fundamental causes [4,5].
Furthermore, a substantial amount of research has reported that
the occurrence of diabetes or macroangiopathy, a complication
of diabetes, can be reduced by actively losing weight at the
beginning of the disease, reinforcing the importance of reducing
body weight and body fat through life habit improvements [2].
Obesity has been reported as the most important factor
associated with metabolic syndrome. Therefore, it is necessary
to recognize obesity as an individual disease and to treat it as
such [6]. In 2014, the World Health Organization (WHO)
reported that more than 1.9 billion adults, 18 years and older,
were overweight. Of those, over 600 million were obese.
Worldwide, the proportion of adults with a body mass index
(BMI) of ≥25 kg/m2 increased between 1980 and 2013 from
28.8% to 36.9% in men, and from 29.8% to 38.0% in women
[7]. According to the Korea National Health and Nutrition
Examination Survey (KNHANES), a domestic epidemiologic
survey performed by the Ministry of Health and Welfare,
national obesity prevalence increased from 26.9% in 1998 to
32.0% in 2011 [8].
With the population aging and standards of living increasing,
interest in personal health is on the rise. With respect to the
advent of a ubiquitous era of advanced information technology,
the field of ubiquitous health (uHealth) care, where information
technology is combined with medical technology, is considered
to be the new high-value industry of the future. uHealth care
refers to the medical service that provides disease prevention,
diagnosis, treatment, and care anytime and anywhere without
physically visiting a hospital. In contrast to current medical
concepts, which emphasize care and treatment after the onset
of disease, uHealth care, along with the advancement of modern
medicine, has the potential to discover and treat diseases in their
early phases through pre-diagnosis and prevention [9]. Thus,
uHealth care is developing into a broad concept with long-term
sustainability for healthy living due to the improved quality and
efficiency of medical services.
To prevent and control obesity, an exercise and diet intervention
is necessary. Among a number of intervention strategies, a
comprehensive body weight control strategy conducted on entire
populations is effective in reducing medical costs and the
economic burden of obesity [5,10-13]. Attempts to manage
exercise and diet intake, the two key goals for weight loss, in
real-time have been performed with limited means through
phone, email, and short message service (SMS) text messaging
[14-16]. However, as mobile phones became more prevalent
and apps with concepts from uHealth care were introduced,
studies were conducted that continued to develop and evaluate
the efficacy of mobile phone-based apps [17-20].
This clinical trial was planned as a multicenter, randomized,
parallel, and open-label study to evaluate the effect of uHealth
care service (hereinafter referred to as SmartCare) on weight
loss in obese patients with metabolic syndrome. A 24-week
randomized controlled trial was conducted to determine whether
SmartCare would be more effective in treating metabolic
syndrome compared with the standard care in the hospital.
Methods
Recruitment
Of the male and female subjects aged ≥20 who visited one of
the two general hospitals (Seoul National University Hospital
and Severance Hospital) in Seoul, obese patients with metabolic
syndrome were recruited. Those whose BMI was ≥25 kg/m2and
who met at least 3 of the 5 following requirements were defined
to have metabolic syndrome and were recruited as a subject in
this trial.
According to the Adult Treatment Panel (ATP) III criteria using
waist circumference cut-off modifications for Asian populations
as suggested by the Asia-Pacific guidelines[21], metabolic
syndrome is defined as having at least 3 of the following factors
(1) central obesity (waist circumference ≥90 cm in men and
≥80 cm in women), (2) hypertriglyceridemia (triglyceride (TG)
≥150 mg/dL), (3) high-density lipoprotein cholesterol (HDL-C)
<40 mg/dL in men and <50 mg/dL in women, (4) hypertension
(blood pressure ≥130/85 mmHg or taking antihypertensive
medication), and (5) hyperglycemia (fasting plasma glucose
(FPG) ≥100 mg/dL or taking antidiabetic medication).
The WHO Regional Office for the Asia Pacific Region
recommends defining obesity in Asians as those with a BMI of
≥25 kg/m2. The Korean Society for the Study of Obesity also
studied the cutoff of BMI for obesity-related disease [22] and
adopted the WHO-recommended definition. Now, Korean
government organizations officially use this definition when
defining and implementing health policies regarding obesity in
Korea.
Subjects taking thyroid hormone or anti-obesity medicine, which
can affect weight, insulin-dependent diabetes, patients with liver
function abnormality (liver somatic index >3 times the normal
maximum level) or renal function impairment (creatinine level
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>1.5 times the normal maximum level), pregnant women, and
inpatients were excluded from this study.
Subjects were recruited through installing institutional review
board- (IRB-) approved banners, posters, and leaflets in the
hospital lobby. As an incentive for the registered test participants
(both intervention and comparison groups), all expenses for
medical treatment, medicine, transportation, and communication
(mobile phones) were provided from the national project budget.
Eligible participants were assigned to the 2 groups with equal
probability according to a randomization code. The
randomization code was prepared by a block randomization
method stratified (according to the enrolling clinical centre) by
a statistician in a clinical trial centre (C&R Research, Seoul,
South Korea). This study was an open labelled trial, blinding
was not done.
The Institutional Review Board of Seoul National University
Hospital approved this study (IRB number: h-1009-095-333).
Intervention Group
Mobile phones for remote monitoring, body composition
monitors (InBody IH-U070B) and pedometers were provided
to the subjects assigned to the intervention group. Each subject
measured his or her own body weight and body composition
using the provided body composition monitor at the same time
every day if possible (a minimum of 3 times per week), and
before breakfast after waking up. After measuring the relevant
values with the body composition monitor, the transmission
terminal (Bluetooth) of the remote monitoring device,
juxtaposed near the transmission terminal of the mobile phone
transmitted the measurement data to the central server in the
SmartCare center via a wireless network. Each subject carried
a pedometer from the time they woke up until they went to bed.
The activity level, indicated as the number of steps taken, was
checked at the same time every day, if possible, and entered
into the mobile phone (inputting before bed was recommended).
Then, the entered data were automatically transmitted to the
central server in the SmartCare center. Physicians or healthcare
personnel at the SmartCare center could retrieve the hospital
admission information, treatment records, name of diagnosed
diseases, diagnostic examinations and functional test results,
and prescription information of the test subjects by connecting
to the hospital information system with the consent of the
subjects. The central server in the SmartCare center transmitted
the feedback based on the measured body weight and body
composition to the mobile phones of the subjects according to
the algorithm of the clinical decision support system (CDSS).
The subjects were able to immediately check the interpretations
and recommendations based on their measured values through
their mobile phones (Figure 1). The educated consultants (nurse,
exercise prescriber, and clinical dietitian) in the SmartCare
center provided various health consultations through the
patients’ telephone inquiries concerning disease management,
health education, recommended exercise, medication, and proper
nutrition. Also, monthly and weekly health reports based on the
individual patient’s measured values and life habit records were
sent directly to the patients through the SmartCare system.
Figure 1. Examples of the SmartCare app.
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Body weight scales and pedometers were provided to the
subjects assigned to the control group. Body weight journals
were distributed to the subjects, and each subject self-measured
and recorded his/her daily weight and waist size (a minimum
of 3 times per week) at the same time (before breakfast) using
waist circumference. Also, they wore a pedometer during daily
activities, which started from the time of waking up in the
morning until bedtime in the evening. They were instructed to
check and record their daily walking amount on the record sheet
just before sleep.
Additionally, the subjects in the control group visited the
hospitals on the same schedule as that of the intervention group
and received anthropometry, consultations with physicians, and
information about their nutrition and exercise.
Study Design
The subjects who met the exclusion criteria and were excluded
from the trial included diabetic patients receiving treatment,
patients with diseases that might affect body weight, or those
who continued to take prescribed medications. The selected
subjects were randomized into a control group that received
basic information on increasing physical activity and controlling
diet habits, or an intervention group that received remote
monitoring and uHealth care service (SmartCare) in addition
to the existing treatment. Pedometers were given to all of the
patients. Additionally, mobile phones and body composition
monitors were provided to the intervention group, and body
weight scales were provided to the control group.
The equipment (mobile phones, weight scales, and pedometers)
were provided to the patients for free through the fund for the
national project.
The subjects were asked to visit the hospitals 4 times during
the 24-week period. Except when screening was performed,
their body weight, body composition, and blood pressure were
checked. A hematology test was performed and changes in their
life habits (eg, diet intake and physical activity) were checked
3 times during the test period; once on the date the subjects
were randomized, once in week 12, and once in week 24 (Figure
2).
Analysis consisted of 2 group sets: intention-to-treat (ITT) and
per protocol (PP). The ITT set included all of the subjects who
were enrolled in this clinical trial and were randomized. When
analyzing efficacy, they were included in the treatment group
into which they were randomized, regardless of the actual
treatment they received. Among the subjects included in the
ITT set, those who completed this clinical trial without material
breach of the protocol were included in the PP set.
Figure 2. Study flowchart and design.
Measurement
When screening was performed, the demographic information
(age, gender, smoking, drinking, and others), medical history,
and medication history of the subjects were investigated and
recorded. Additionally, an electrocardiogram (ECG) was
performed at the screening visit after resting for at least 5
minutes. When clinically significant test results were observed,
the investigator determined whether to enroll the subject in the
experiment.
The laboratory tests were conducted at screening, baseline, week
12, and week 24, and the tests included alanine aminotransferase
(ALT), aspartate aminotransferase (AST), creatinine, lipid
profile (total cholesterol, HDL-C, and TG), fasting blood sugar
(FBS), and baseline glycosylated hemoglobin (HbA1c).
However, ALT, AST, and creatinine tests were performed only
at screening to determine trial eligibility. Lipid profiles and
blood glucose tests were performed after fasting.
Weight change was the primary outcome and was evaluated
with percent body fat at baseline, week 12, and week 24 and
measured by nurses using a portable bioelectrical impedance
analysis device (InBody U20, Seoul, Korea).
The level of physical activity was assessed and categorized
using the International Physical Activity Questionnaire (IPAQ)
at baseline, week 12, and week 24. The amount of physical
activity each week was calculated with a continuous variable,
the Metabolic Equivalent of Task (MET) using the following
equation:
Total MET min/week = [walking METs×min×days] + [moderate
METs×min×days] + [vigorous METs×min×days])
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Concerning the method for measuring the caloric intake
variables, daily meal record cards (3-day recall dietary
assessment) were distributed to the subjects during their initial
visit and the subjects were instructed to write their own 3-day
meal record just before the baseline visit, the next visit after
12weeks, and the final visit after 24weeks. The self-completed
daily meal records were collected from the subjects during their
final visit and the dietitian performed the calorie calculation
using the nutrient evaluation program CAN-Pro 3.0 software
(The Korean Nutrition Society, 2006) [23].
Statistical Analysis
Each group initially consisted of 167 subjects chosen using a
5% significance level, 90% power, and estimating the mean
difference in weight change between the 2 groups to be 1.81 kg
(SD 4.81 and 5.36 kg). Considering a 25% drop out rate, the
final sample size consisted of 223 subjects for each group
(N=446 subjects) [24-27].
Descriptive statistics including the number of observed subjects,
mean, and median (range) of body weight measured at baseline,
week 12, and week 24, and the changes in measured values at
week 24 compared to baseline were presented for each group.
To identify the difference between the groups with respect to
body weight changes at week 24 compared to the baseline,
analysis of covariance (ANCOVA), including the clinical trial
institution and the body weight at baseline as covariates, was
performed.
For continuous data, such as changes in BMI, body fat
percentage, waist measurement, lipid profile, blood pressure,
the number of metabolic syndrome elements, diet intake (kcal),
physical activity, number of steps taken, and weight to measure
physical activity, descriptive statistics including the number of
observed subjects, mean, and median (range) were presented
for each group. To identify the difference between the groups
at week 24 compared to the baseline, ANCOVA or rank
transformation ANCOVA was performed. When conducting
ANCOVA, the clinical trial institution and the baseline values
of relevant parameters were set as covariates.
For categorical data including the ratio of the subjects whose
body weights decreased by ≥10%, the changes in the prevalence
rates of metabolic syndrome and the changes in life habits (ie,
smoking and drinking, the frequency, rates, and 95% confidence
interval were presented for each group. To identify the
difference in rates between the groups at weeks 12 and 24, the
Cochran-Mantel-Hansel (CMH) test was performed using the
clinical trial institution as a covariate.
To identify the satisfaction level of the subjects (only for
intervention group), the scores of the satisfaction survey items
related to the usage convenience of the devices were measured
at weeks 12 and 24, and descriptive statistics including the
number of observed subjects, mean, and median (range) on the
measured scores were presented.
The adverse events occurring after randomization were collected
and analyzed. The frequency, percentage, and 95% confidence
intervals of the adverse events and serious adverse events were
presented. To find the difference between the groups in the
frequency of adverse and serious adverse events, Pearson’s
chi-square test or Fisher’s exact test was performed. The adverse
and serious adverse events were coded according to the Medical
Dictionary for Regulatory Activities (MedDRA) system organ
class (SOC) and preferred term (PT), and the number of types,
frequency, and the number of cases of the coded adverse events
were presented. Additionally, the numbers of adverse events
occurrences and percentages were presented by severity, and a
detailed statement on the serious adverse events was presented.
All analyses were conducted using STATA version 12.1
(StatCorp, Houston, TX) for Windows software. P values less
than .05 were considered statistically significant.
Results
Subject Participation
During the clinical trial, a total of 661 subjects went through
screening, and 442 of them were identified as subjects with
metabolic syndrome. Subjects were randomized into the
intervention (N=212) or control (N=210) group. Therefore, the
ITT set included a total of 422 subjects. Because a total of 31
(14.6%, 31/212) subjects dropped out of the intervention group
during the observation period of 24 weeks, 181 (85.3%,
181/212) subjects completed the trial. A total of 57 (27.1%,
57/210) subjects dropped out of the control group, and 153
(72.9%, 153/210) subjects completed the trial. Thus, the PP set
included a total of 334 subjects (Figure 3).
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Figure 3. Selection of the study participants.
Demographic Data and Characteristics of Subjects
Prior to Treatment
The conditions of the subjects before providing medical service
were compared between groups, including the demographic
information of the subjects included in the ITT set. The mean
ages were 46.78 years (SD 13.11) for the intervention group
and 50.35 years (SD 14.24) for the control group, indicating a
statistically significant difference in the age distribution between
the groups (P=.008). However, there was no significant
difference between the 2 in terms of age groups (P=.269). The
number of male and female subjects in the intervention group
were 113 (53.3%, 113/212and 99 (46.7%, 99/212), respectively.
In the control group, the number of male subjects was 102
(48.6%, 102/210) and the number of female subjects was 108
(51.4%, 108/210) demonstrating no statistically significant
difference in gender distribution between the groups (P=.331).
The mean BMI was 29.42 kg/m2 (SD 3.53) for the intervention
group and 29.40kg/m2 (SD 3.39) for the control group,
indicating no statistically significant difference in the
distribution of BMI between the groups (P=.934).
With respect to the education level of subjects in the 2 groups,
136 (64.2%, 136/212) subjects in the intervention group were
“college graduates or higher”, whereas 109 (51.9%, 109/210)
in the control group were “college graduates or higher”.
Statistically significant differences in education levels were
observed among the “elementary school graduates” and “college
graduates or higher” (P=.001). Moreover, body weight (P=.343),
height (P=.131), smoking (P=.475), and drinking (P=.726) were




The body weights at baseline, week 12, and week 24 were
summarized in the descriptive statistics, and the body weight
changes at week 24 compared to baseline were assessed. In the
ITT set, the mean body weights of the intervention group at
baseline and week 24 were 81.13 kg (SD 14.77) and 77.87 kg
(SD 13.99), respectively. The mean body weight at week 24
decreased by 2.21 kg (SD 3.60) compared to the weight at
baseline, which was statistically significant (P<.001). The mean
body weights of the control group at baseline and week 24 were
79.74 kg (SD 15.28) and 77.02 kg (SD 13.33), respectively.
The mean body weight at week 24 decreased by 0.77 kg (SD
2.77) compared to baseline, which was statistically significant
(P<.001). In the comparison between the groups, the mean body
weight change of the intervention group at week 24 compared
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to baseline was significantly higher than that of the control
group (P<.001) (Table 1).
In the PP set, the mean body weights of the intervention group
at baseline and week 24 were 79.93 kg (SD 13.55) and 77.64
kg (SD 13.91), respectively. The mean body weight at week 24
decreased by 2.29 kg (SD 3.62) compared to baseline, which
was statistically significant (P<.001). The mean body weights
of the control group at baseline and week 24 were 77.89 kg (SD
13.68) and 77.02 kg (SD 13.28), respectively. The mean body
weight at week 24 decreased by 0.86 kg (SD 2.84) compared
to baseline, which was statistically significant (P<.001). As in
the ITT set, the mean body weight change of the intervention
group at week 24 compared to baseline was significantly higher
than that of the control group (P<.001) (Table 2).
Table 1. Changes in weight (baseline versus 24 weeks) in the ITT set.
Between groups P valueControl groupIntervention groupWeight, kg
Baseline
209212n
79.74 (15.28)81.13 (14.77)Mean (SD)
76.9079.85Median
54.00, 141.1055.20, 144.00Min, max
Week 12
179196n
76.67 (13.26)77.85 (13.46)Mean (SD)
74.1076.85Median
53.40, 118.1049.80, 135.70Min, max
Week 24
181196n
77.02 (13.33)77.87 (13.99)Mean (SD)
75.1077.35Median
53.20, 117.9050.10, 141.00Min, max
Change W24 a
181196n
<.001b-0.77 (2.77)-2.21 (3.60)Mean (SD)
-0.70-2.10Median
-20.40, 6.60-17.00, 5.60Min, max
<.001c<.001cWithin group, P value
aChange W24=week 24−baseline
bANCOVA using the site and baseline weight as covariates
cPaired t test
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Table 2. Changes in weight (baseline versus 24 weeks) in the PP set.
Between groups P valueControl groupIntervention groupWeight, kg
Baseline
153181n
77.89 (13.68)79.93 (13.55)Mean (SD)
74.7079.10Median
54.00, 120.1055.20, 135.40Min, max
Week 12
152181n
76.61 (13.21)77.62 (13.38)Mean (SD)
74.0076.80Median
53.40, 118.1049.80, 135.70Min, max
Week 24
153181n
77.02 (13.28)77.64 (13.91)Mean (SD)
75.0076.80Median
53.20, 117.9050.10, 141.00Min, max
Change W24 a
153181n
<.001b-0.86 (2.84)-2.29 (3.62)Mean (SD)
-0.80-2.10Median
-20.40, 6.60-17.00, 5.60Min, max
<.001c<.001cWithin group P value
aChange W24=week 24−baseline
bANCOVA using the site and baseline weight as covariates
cPaired t test
Secondary Efficacy Evaluation
Among the secondary efficacy evaluation parameters, BMI,
rate of body fat, decrement of waist measurement, and diet habit
improvement from baseline to week 24 were superior in the
intervention group compared with the control group (body fat
rate P=.001, diet habit P=.012, and others P<.001). In particular,
the mean BMIs of the intervention group in the ITT set at
baseline and week 24 were 29.42 kg/m2 (SD 3.53) and 28.33
kg/m2 (SD 3.46), respectively. The mean BMI at week 24
decreased by 0.83 kg/m2 (SD 1.31) compared to baseline, which
was statistically significant (P<.001). The mean BMIs of the
control group at baseline and week 24 were 29.40 kg/m2 (SD
3.39) and 28.74 kg/m2 (SD 2.88), respectively. The mean BMI
at week 24 decreased by 0.28 kg/m2 (SD 1.03) compared to
baseline, which was statistically significant (P=<.001). In the
comparison between the groups, the change in BMIs of the
intervention group at week 24 compared to baseline was
significantly higher than that of the control group (P<.001)
(Table 3).
A similar trend was observed in the PP set (Table 4). However,
the ratio of the patients whose body weight decreased by ≥10%
and the lipid profile, blood pressure, prevalence of metabolic
syndrome, change in the number of metabolic syndrome
elements, smoking rate, drinking rate, and physical activity were
not statistically significantly different between the groups.
JMIR mHealth uHealth 2015 | vol. 3 | iss. 3 | e83 | p. 8http://mhealth.jmir.org/2015/3/e83/
(page number not for citation purposes)
Oh et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Table 3. Changes in BMI (baseline versus 24 weeks) in the ITT set.
Between groups P valueControl groupIntervention groupBMI, kg/m2
Baseline
209212n
29.40 (3.39)29.42 (3.53)Mean (SD)
28.9028.70Median
24.90, 41.8024.90, 46.80Min, max
Week 12
179196n
28.59 (2.84)28.35 (3.25)Mean (SD)
28.1027.85Median
24.00, 38.9022.10, 40.10Min, max
Week 24
181196n
28.74 (2.88)28.33 (3.46)Mean (SD)
28.2027.55Median
23.90, 39.7022.60, 41.40Min, max
Change W24 a
181196n
<.001b-0.28 (1.03)-0.83 (1.31)Mean (SD)
-0.20-0.80Median
-6.70, 2.40-5.80, 2.20Min, max
<.001c<.001cWithin the group P value
aChange W24=week 24−baseline
bANCOVA using the site and baseline weight as covariates
cPaired t test
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Table 4. Changes in BMI (baseline versus 24 weeks) in the PP set.
Between groups P valueControl groupIntervention groupBMI, kg/m2
Baseline
153181n
29.08 (2.90)29.18 (3.13)Mean (SD)
28.8028.60Median
25.00, 39.7025.00, 41.40Min, max
Week 12
152181n
28.60 (2.76)28.34 (3.23)Mean (SD)
28.1027.80Median
24.00, 38.5022.10, 40.10Min, max
Week 24
153181n
28.74 (2.81)28.32 (3.44)Mean (SD)
28.3027.50Median
23.90, 39.7022.60, 41.40Min, max
Change W24 a
153181n
<.001b-0.33 (1.04)-0.86 (1.32)Mean (SD)
-0.30-0.80Median
-6.70, 2.40-5.80, 2.20Min, max
<.001c<.001cWithin the group p-value
aChange W24=week 24−baseline
bANCOVA using the site and baseline weight as covariates
cPaired t test
Subject Satisfaction
The convenience of device usage, satisfaction with the
SmartCare center service, and overall satisfaction of the remote
monitoring were determined at weeks 12 and 24, based on a
5-point scale where 5 corresponded to highly satisfied. At week
12, the convenience of device usage, satisfaction with the
SmartCare center service, and overall satisfaction of the remote
monitoring were found to be 3.54 (SD 1.02), 4.08 (SD 0.86),
and 3.93 (SD 0.86), respectively. At week 24, the satisfaction
with the convenience of device usage was 3.52 (SD 0.99),
SmartCare center service was 4.14 (SD 0.88), and overall
satisfaction of the remote monitoring was 3.92 (SD 0.85).
Safety Results
The rates of adverse events in the intervention group and control
group were 14.2% (30/212, 43 cases) and 13.3% (28/210, 40
cases), respectively. The rates of serious adverse events in the
intervention group and control group were 1.4% (3/212, 3 cases)
and 2.4% (5/210, 5 cases), respectively. Due to serious adverse
events, the intervention group showed 1 case of ankle fracture,
and the control group showed 1 case of dislocated vertebra,
stress urinary incontinence, and knee operation.
After the physical examination, no subject in either of the 2
groups had abnormalities at week 24 after showing no
abnormalities at baseline.
Pulse reduction at week 24 compared to baseline was 2.84
beats/min (SD 10.01) for the intervention group and 0.94
beats/min (SD 8.47) for the control group. The difference
between the groups was statistically significant (P=.049), but




To the best of our knowledge, this study was the first domestic
government project to estimate the usefulness of SmartCare in
managing chronic disease. Weight decrement after 24 weeks
from the baseline, a primary efficacy evaluation parameter, was
2.21 kg (SD 3.60) for the intervention group and 0.77 kg (SD
2.77) for the control group, and the intervention group showed
a higher rate of reduction compared to the other group (P<.001).
Among the secondary efficacy evaluation parameters, BMI,
body fat rate, decrement of waist measurement, and diet habit
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improvement ratings after 24 weeks were superior in the
intervention group (body fat rate P<.001, diet habit P=0.012,
and others P<.001). The proportion of patients whose body
weight decreased by ≥10%, the lipid profiles, blood pressure,
prevalence of metabolic syndrome, change in the number of
metabolic syndrome elements, smoking rate, drinking rate, and
physical activity were not significantly different.
uHealth care, an abbreviation for ubiquitous health care, refers
to a health care medical service in which information and
communication technologies are combined with medicine so
that patients can be provided with prevention, diagnosis,
treatment, and follow-up services anytime and anywhere, even
if they do not directly visit hospitals [28,29]. uHealth care is a
medical service developed to collect real-time health-related
information without limits pertaining to time or location, and
to perform continuous monitoring and treatment to examine
health conditions in advance and prevent diseases, rather than
solely providing treatment after the onset of disease. Because
of the sudden increase in medical costs due to population aging
and the increase of patients with chronic diseases in modern
society, the need for the development of such a service is
increasing, as is the need to build a cost-effective medical system
and improve the quality of health and medical treatment services
[30].
This clinical trial was designed in consideration of such
situations. Here, we compared the SmartCare service (uHealth
care) with the existing treatment to evaluate the effect of the
service on body weight, as well as its safety in obese patients
who need constant monitoring.
Overweight and obesity due to a Westernized diet and lack of
exercise are serious problems all over the world and have
adverse effects not only on personal health but also on national
economies. To solve these problems, an approach including
prevention should be taken, rather than relying only on medical
treatment after the occurrence of disease. In addition, long-term
treatments such as improving individual life habits through
continuous care are paramount [31].
Metabolic syndrome is a disease caused by insulin resistance,
which is usually linked to overweight and obesity. Thus, weight
control is vital for this condition. To lose weight, exercise and
a controlled diet are absolutely important [5,11,32,33].
Practicing diet therapy can cut down on fat as well as lean body
mass. This drops the basic metabolic rate, easily causing the
yo-yo effect where the patient gains weight even from small
food intake.
Comparison With Prior Work
Various attempts to prevent obesity have been made, including
a case where healthy eating habits and adequate exercise to
maintain reduced weight were carried out in a community setting
[34,35]. Cases where competition among members to maintain
healthy lifestyles and to lose weight was encouraged with the
use of aggressive measures have been reported in a timely
fashion with the introduction of telemedicine [9]. However, the
exchange of food and exercise information through the Internet
was found to be more effective in weight loss and maintenance
than traditional methods of self-maintenance and
self-management [36].
This clinical trial paired the SmartCare service together with
the existing treatment (intervention group) to only the existing
treatment (control group) and compared the mean change in
body weight at week 24 to baseline between the 2 groups. The
test results showed significantly higher changes in body weight
in the intervention group than in the control group, proving that
the SmartCare service shows higher efficacy when combined
with the existing treatment than when only the existing treatment
was provided. Additionally, we obtained results consistent with
the primary efficacy evaluation in BMI, body fat rate, and waist
measurements, which are directly related to obesity and body
weight. In the satisfaction survey for the SmartCare service,
convenience of device usage, satisfaction with the SmartCare
Center service, and overall satisfaction with remote monitoring,
all received responses of were 'satisfactory' or 'very satisfactory'
from ≥50% of the users. Studies conducted in other countries
have found similar results. These studies showed that various
methods implemented to motivate patients to increase physical
activity, control their diets, and maintain healthy life habits
mostly produced positive results [16,20,37-44].
Study Strengths and Limitations
Based on the number of times information was entered on the
mobile phone for diet intake and the amount of exercise, the
subgroup analysis of this study revealed that the scope of weight
loss was considerably increased. Through this revelation, the
level of interest in using uHealth in real-time was found to be
an important variable that can heavily influence the level of
weight loss. The difference between this study compared to
previous studies from abroad is that the mean age of the subjects
was between the mid-40s to the early 50s, older than the ages
of the subjects included in the other studies. Thus, this study is
meaningful in that it showed that the concept of uHealth is not
the exclusive property of younger generations who use advanced
devices. It showed that anyone who uses a mobile phone in
modern society could use uHealth accordingly.
However, the fact that highly educated young individuals were
assigned to the intervention group, despite the random selection,
may work as a selection bias when evaluating the effects of
SmartCare. Nonetheless, this research also revealed that the
number of people who failed in the control group was twice
that of the intervention group, thereby suggesting the possibility
that SmartCare increased participants' adherence to a weight
loss program compared to weight loss means using traditional
methods.
On the other hand, the rates of the subjects whose body weight
decreased by ≥10%, lipid profiles (total cholesterol, HDL-C,
low-density lipoprotein cholesterol (LDL-C), and TG), changes
in systolic and diastolic blood pressure, rate of patients with
metabolic syndrome, change in the number of metabolic
syndrome elements, smoking rate, and drinking rate were not
statistically significantly different between the intervention and
control groups. There are a few possible causes for this
observation. First, subjects with reduced weight during the initial
phase of the study showed a tendency to have slight increases
in weight towards the latter phase of the study. Second, it is
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difficult to confirm whether eating habits, specifically the control
of calories and salt intake, improved compared to the increased
physical activity and weight loss effect. The risk factors of
metabolic syndrome are expected to decrease when the effects
of weight reduction are sustained for a long period of time, and
such benefits can be confirmed with a longer research plan for
weight maintenance. Furthermore, if the reduction can be
quantitatively proved through feedback regarding the controlled
salt and total calorie intake to improve eating habits, it may be
possible to observe the number of metabolic syndrome factors,
such as blood pressure and the change in the lipid profile, of
the participants through subgroup analysis.
Conclusions
Through analyzing obesity evaluation indexes such as BMI and
including weight, body fat rate, and waist measurements, we
found that the SmartCare service is an effective way to control
the weight of obese patients with metabolic syndrome.
The positive effects of the development of uHealth on the
medical field can influence not only health care providers but
also various fields, including health care centers and network
operators, can provide medical service anytime and anywhere
without patients having to visit hospitals during operating hours,
and can provide individually customized service for health
improvement and disease prevention for identical conditions in
contrast to the usual patient-doctor relationship [45].
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